Rocket Pharmaceuticals Inc RCKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
-
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
-
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
-
Rocket Pharmaceuticals Shares Slide After FDA Rejects Kresladi
-
FDA Turns Away Rocket Pharma's Gene Therapy, Seeks More Data
-
FDA Extends Review of Rocket Pharma's Proposed Kresladi
-
Rocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease Treatment
Trading Information
- Previous Close Price
- $16.06
- Day Range
- $16.03–16.52
- 52-Week Range
- $15.98–32.53
- Bid/Ask
- $16.10 / $16.75
- Market Cap
- $1.49 Bil
- Volume/Avg
- 1.3 Mil / 846,345
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 268
- Website
- https://www.rocketpharma.com
Comparables
Valuation
|
Metric
|
RCKT
|
TERN
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 14.90 |
Price/Book Value | 3.80 | 2.64 | 2.73 |
Price/Sales | — | — | 6.58 |
Price/Cash Flow | — | — | 14.11 |
Price/Earnings
RCKT
TERN
UTHR
Financial Strength
|
Metric
|
RCKT
|
TERN
|
UTHR
|
|---|---|---|---|
Quick Ratio | 7.42 | 20.57 | 3.92 |
Current Ratio | 7.79 | 21.02 | 4.35 |
Interest Coverage | −143.43 | — | 22.67 |
Quick Ratio
RCKT
TERN
UTHR
Profitability
|
Metric
|
RCKT
|
TERN
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −41.09% | −28.87% | 16.95% |
Return on Equity (Normalized) | −46.72% | −30.36% | 20.53% |
Return on Invested Capital (Normalized) | −47.69% | −34.37% | 16.62% |
Return on Assets
RCKT
TERN
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vsbnghvkht | Zsdc | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cbftkkkkb | Ydkgt | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dxbxsbnkc | Clvwyd | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mvmnndkp | Ycntljv | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Swblnzg | Vxvt | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Bxsxyflrv | Jgndy | $28.5 Bil | |||
| Moderna Inc
MRNA
| Glhdhvp | Zrnfd | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Mygczbqw | Lnqr | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vllhbsh | Hwpgp | $13.0 Bil | |||
| Incyte Corp
INCY
| Qklxhfkmc | Hwvvy | $12.9 Bil |
United States